Johnson & Johnson vaccine and thrombosis risk, what the Cts says

On the Johnson & Johnson vaccine, despite having similarities with the AstraZeneca anti-covid vaccine, at the moment the data “do not allow us to draw conclusive assessments with respect to the benefit / risk ratio”. This is what is stated in the report n. 27 of the Cts, yesterday, in which the opinion was provided on the use of the AstraZeneca vaccine from the age of 60 and on the possibility, for those who have already taken the first dose, to complete the cycle with an mRna vaccine. The Janssen vaccine, notes the Technical Scientific Committee, is “characterized by the advantage of single administration, a peculiarity that can be of particular benefit in certain categories of the population”. But “any evidence, in the national and international context, of thromboembolic phenomena after the Janssen vaccine must be subject to careful and constant monitoring through the pharmacosurveillance and vaccine-surveillance procedures”. The committee, according to the minutes, notes that “the Janssen vaccine is recommended, also in light of what is defined by the Cts of Aifa, for subjects over the age of 60. If specific situations arise in which the conditions of advantage are evident of the single administration and in the absence of other options, the Janssen vaccine should preferentially be used, subject to the opinion of the territorially competent Ethics Committee “.